Factor Xa Inhibitors

Factor Xa Inhibitor

Pulmonary Embolism

Venous Thrombosis

<section class="Section" data-sectioncode="34089-3"><a name="s11"></a><a name="section-10"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">ELIQUIS (apixaban), a factor Xa (FXa) inhibitor, is chemically described as 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1<span class="Italics">H</span>-pyrazolo[3,4-<span class="Italics">c</span>]pyridine-3-carboxamide. Its molecular formula is C<span class="Sub">25</span>H<span class="Sub">25</span>N<span class="Sub">5</span>O<span class="Sub">4</span>, which corresponds to a molecular weight of 459.5. Apixaban has the following structural formula:</p><div class="Figure"><a name="id15675537"></a><img alt="Apixaban Chemical Structure" src="apixaban-struct.jpg"/></div><p>Apixaban is a white to pale-yellow powder. At physiological pH (1.2-6.8), apixaban does not ionize; its aqueous solubility across the physiological pH range is ~0.04 mg/mL.</p><p>ELIQUIS tablets are available for oral administration in strengths of 2.5 mg and 5 mg of apixaban with the following inactive ingredients: anhydrous lactose, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate. The film coating contains lactose monohydrate, hypromellose, titanium dioxide, triacetin, and yellow iron oxide (2.5 mg tablets) or red iron oxide (5 mg tablets).</p></section>

ELIQUIS

apixaban

apixaban 2.5 MG Oral Tablet

Eliquis

apixaban 2.5 MG Oral Tablet [Eliquis]

apixaban 5 MG Oral Tablet

apixaban 5 MG Oral Tablet [Eliquis]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information 

Medication Guide 

Submit MSL Request 

Pharmacy List 

Formulary Coverage 

Online Sample Form 

Reimbursement Information

Coverage Authorization Request 

Coverage Authorization Appeals 

Benefit Investigation

Eliquis 360 HCP Portal

Enroll in Patient Savings Program 

Free 30 Day Trial 

Other HCP Resources 

About Eliquis: Prophylaxis of Deep Vein Thrombosis after Hip or Knee Replacement Surgery 

About Eliquis: Nonvalvular Atrial Fibrillation Stroke Risk Reduction 

FAQs: Nonvalvular Atrial Fibrillation Stroke Risk Reduction 

Side Effects: Nonvalvular Atrial Fibrillation Stroke Risk Reduction 

Taking Eliquis: Nonvalvular Atrial Fibrillation Stroke Risk Reduction 

Doctor Discussion Guide: Nonvalvular Atrial Fibrillation Stroke Risk Reduction 

About Eliquis: Deep Vein Thrombosis & Pulmonary Embolism 

FAQs: Deep Vein Thrombosis & Pulmonary Embolism

Taking Eliquis: Deep Vein Thrombosis & Pulmonary Embolism

Side Effects: Deep Vein Thrombosis & Pulmonary Embolism 

Doctor Discussion Guide: Deep Vein Thrombosis & Pulmonary Embolism

Eliquis 360 Support Program 

Instructions For Use: Prophylaxis of Deep Vein Thrombosis after Hip or Knee Replacement Surgery 

Instructions For Use: Nonvalvular Atrial Fibrillation Stroke Risk Reduction

Instructions For Use: Deep Vein Thrombosis & Pulmonary Embolism

Eliquis Start Guide: Nonvalvular Atrial Fibrillation Stroke Risk Reduction

Eliquis Start Guide: Deep Vein Thrombosis and Pulmonary Embolism 